Sheet	1	of	1
OHOCE	_ 1	OI	1

\0,'.	SubStitut
JAN 0 2	Substitut
E	

Stitute Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 07064-009002

Application No. 09/940,235

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant Rajesh Kumar, et al.

August 27, 2001

Filing Date

Group Art Unit 1652

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						_
	AB						
	AC .						
	AD						
	AE						
	AF						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Desig.	Document	Publication	Country or			Translation		
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AG							
	AH							
	AI							
	AJ							
	AK							

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner	Desig.						
Initial	ID Document						
85	AL	Pilar Alcala, et al., "Engineering of Escherichia coli β-galactosidase for solvent display of a Functional scFV Antibody Fragment," Federation of Europeam Biochemical Societies, pp 115-118 (2002).					
	AM	Sven-Olof Enfors, "Control of in vivo Proteolysis in the Production of Recombinant Proteins," <i>TibTech</i> , Vol. 10: pp 310-315 (1992).					
	AN	CF Ford, et al., 'Fusion Tails for the Recovery and Purification of Recombinar Proteins," <i>Protein Expr Purification</i> , pp. 95-107 (1991).					
-	AO	Richard J. Jenny, et al., "A Critical Review of the Methods for Cleavage of Fusion Proteins with Thrombin and Factor Xa," Protein Expression and Purification, Vol. 31 pp. 1-11(2003).					
	AP	Shannon A. Marshall, et al. "Rational Design and Engineering of Therapeutic Proteins," Drug Discovery Today, Vol. 8, No. 5 pp. 212-221 (2003).					
4	AQ	Didier Picard, "Regulation of Protein Function Through Expression of Chimaeric Proteins," Current Opinion in Biotechnology, Vol: 5 p. 511-515 (1994).					

	1			
Examiner Signature (Date Considered		
	r)ana	ス	In	n4
	<u> </u>		~	0 1
EXAMINER: Initials citation consid	dered. Draw line through citation if no	ot in conformance and not co	nsider	ed. Include copy of this form with
next communication to applicant.	•			
			Su	bstitute Disclosure Form (PTO-1449)